EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome

被引：11

作者：

Tiefenbacher, Andreas ^{[1
]}

Pirker, Robert ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Med 1, Wahringer Gurtel 18-20, A-1090 Vienna, Austria

来源：

JOURNAL OF THORACIC DISEASE | 2017年 / 9卷 / 11期

关键词：

CHEMOTHERAPY PLUS CETUXIMAB; PHASE-III TRIAL; OPEN-LABEL; BEVACIZUMAB; GROWTH; OSIMERTINIB; MULTICENTER; GEMCITABINE; CISPLATIN; ERLOTINIB;

D O I：

10.21037/jtd.2017.10.02

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页码：4208 / 4211

页数：4

共 19 条

[1] Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial [J].

Ahn, M. -J. ;

Yang, J. ;

Yu, H. ;

Saka, H. ;

Ramalingam, S. ;

Goto, K. ;

Kim, S. -W. ;

Yang, L. ;

Walding, A. ;

Oxnard, G. R. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) :S115-S115

[2] Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) [J].

Dearden, S. ;

Stevens, J. ;

Wu, Y. -L. ;

Blowers, D. .

ANNALS OF ONCOLOGY, 2013, 24 (09) :2371-2376

[3] MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents [J].

Fan, Weiwen ;

Tang, Zhe ;

Yin, Lihong ;

Morrison, Bei ;

Hafez-Khayyata, Said ;

Fu, Pingfu ;

Huang, Honglian ;

Bagai, Rakesh ;

Jiang, Shan ;

Kresak, Adam ;

Howell, Scott ;

Vasanji, Amit ;

Flask, Chris A. ;

Halmos, Balazs ;

Koon, Henry ;

Ma, Patrick C. .

CANCER RESEARCH, 2011, 71 (13) :4494-4505

[4]

Herbst RS, 2017, LANCET ONCOL

[5] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].

Mok, T. S. ;

Wu, Y. -L. ;

Ahn, M. -J. ;

Garassino, M. C. ;

Kim, H. R. ;

Ramalingam, S. S. ;

Shepherd, F. A. ;

He, Y. ;

Akamatsu, H. ;

Theelen, W. S. M. E. ;

Lee, C. K. ;

Sebastian, M. ;

Templeton, A. ;

Mann, H. ;

Marotti, M. ;

Ghiorghiu, S. ;

Papadimitrakopoulou, V. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640

[6] Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation [J].

Oxnard, Geoffrey R. ;

Arcila, Maria E. ;

Sima, Camelia S. ;

Riely, Gregory J. ;

Chmielecki, Juliann ;

Kris, Mark G. ;

Pao, William ;

Ladanyi, Marc ;

Miller, Vincent A. .

CLINICAL CANCER RESEARCH, 2011, 17 (06) :1616-1622

[7] Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer [J].

Pirker, Robert .

CURRENT OPINION IN ONCOLOGY, 2016, 28 (02) :115-121

[8] Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update [J].

Pirker, Robert .

CURRENT OPINION IN ONCOLOGY, 2015, 27 (02) :87-93

[9] What is the best strategy for targeting EGF receptors in non-small-cell lung cancer? [J].

Pirker, Robert .

FUTURE ONCOLOGY, 2015, 11 (01) :153-167

[10] EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study [J].

Pirker, Robert ;

Pereira, Jose R. ;

von Pawel, Joachim ;

Krzakowski, Maciej ;

Ramlau, Rodryg ;

Park, Keunchil ;

de Marinis, Filippo ;

Eberhardt, Wilfried E. E. ;

Paz-Ares, Luis ;

Stoerkel, Stephan ;

Schumacher, Karl-Maria ;

von Heydebreck, Anja ;

Celik, Ilhan ;

O'Byrne, Kenneth J. .

LANCET ONCOLOGY, 2012, 13 (01) :33-42

← 1 2 →